WASHINGTON, D.C. – The Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center announces a three-part symposium, titled "Fighting a Smarter War Against Cancer: Linking Policy to the Patient," to be held Thursday, December 1 through Saturday, December 3, 2011 on the campuses of Georgetown University and Georgetown University Law Center in Washington, D.C.
The mission of the Ruesch Center is to refocus national efforts on this set of deadly diseases, aiming to fight a smarter war against cancer. Combining expertise in molecular medicine, translational research, and a patient-centered philosophy, the Ruesch Center strives to improve treatment outcomes through research, care and advocacy. Ruesch Symposium 2011 will convene top thought leaders and health care practitioners from the U.S. and around the world to discuss cancer care in relation to public policy, value and personalized medicine.
Topics include: “Health Care Reform: Opportunity or Sacrifice?”; “Defining Value in Cancer Care;” and “Navigating Cancer Care: What Every Patient Should Know.” Speakers from academia, governmental agencies, pharmaceutical industry and the insurance industry will address issues involving the healthcare policy, law, medicine, and the regulatory process.
Spearkers include: Louis B. Jacques, M.D., Centers for Medicare & Medicaid Services; David J. Kerr, M.D., Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics; Ira M. Klein, M.D., Aetna, Inc.; Gregory H. Reaman, M.D., U.S. Food and Drug Administration; Mona Sabharwal, B.Sc.Phm., Pharm.D., R.Ph., Pan-Canadian Oncology Drug Review; Margaret Mahon, Ph.D., R.N., F.A.A.N., George Mason University; Thomas J. Smith, M.D., F.A.C.P., The Johns Hopkins Medical Institutions; Paul J. Wallace, M.D., Center for Comparative Effectiveness Research, The Lewin Group; Jordan D. Berlin, M.D., Vanderbilt-Ingram Cancer Center; Antonio Tito Fojo, M.D., Ph.D., National Cancer Institute; and Louis M. Weiner, M.D., Georgetown Lombardi.
The symposium is free and open to the public and attendees are invited to attend one, two or all three days.
For more information and to register, visit www.rueschcenter.org/symposium2011.
About the Ruesch Center
The Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, part of Georgetown Lombardi Comprehensive Cancer Center, was founded in 2009 to refocus national efforts on curing cancers of the gastrointestinal tract. Combining expertise in molecular medicine, translational research and a patient-centered philosophy, the Ruesch Center seeks to realize the dream of individualized curative therapies through research, care and advocacy.
The center is directed by John L. Marshall, MD, a global leader in the research and development of drugs for colon cancer and other GI cancers. Learn more at www.rueschcenter.org.
About Georgetown Lombardi Comprehensive Cancer Center
Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Georgetown Lombardi is one of only 40 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to http://lombardi.georgetown.edu.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2010-11, GUMC accounted for 85 percent of the university’s sponsored research funding.